Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.47 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | CCR2 | P41597 | 5/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
| ▸ | FEN1 | P39748 | 1/20 | 0.44 |
| ▸ | DBH | P09172 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7506861 | 0.85 | ALDH1A1 (0.43) | ALDH1A1PKMCYP3A4CYP2C19GAA | |
| SCHEMBL4484502 | 0.83 | GAA (0.66) | ALDH1A1CYP3A4CYP2C19GAATSHR | |
| SCHEMBL4479607 | 0.78 | P2RX7 (0.67) | ALDH1A1PKMCYP3A4CYP2C19GAA | |
| SCHEMBL11607380 | 0.77 | KDM4E (0.47) | ALDH1A1CYP3A4CYP2C19GAACCR2 | |
| SCHEMBL7508385 | 0.76 | ATM (0.69) | ALDH1A1PKMCYP3A4CYP2C19GAA | |
| SCHEMBL3165877 | 0.75 | P2RX7 (0.44) | ALDH1A1PKMCYP3A4CYP2C19TSHR | |
| SCHEMBL3353651 | 0.73 | KDM4E (0.63) | ALDH1A1CYP3A4CYP2C19GAAEGLN1 | |
| SCHEMBL2314932 | 0.72 | SCD (0.66) | — | |
| SCHEMBL2316656 | 0.72 | SCD (0.66) | — | |
| SCHEMBL16759801 | 0.72 | ALDH1A1 (0.40) | ALDH1A1PKMCYP3A4CYP2C19TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1987019-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS 5HT2/D3 MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-11-05 | — | — | EP | claimed |
| WO-2007093540-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS 5HT2/D3 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-23 | — | — | WO | claimed |
| US-20070197531-A1 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | claimed |
| US-8039490-B2 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2011-10-18 | — | — | US | disclosed |
| EP-1987019-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS 5HT2/D3 MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007093540-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS 5HT2/D3 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| US-20070197531-A1 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197531-A1 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HTR2A, HTR3A, HTR2C | ALDH1A1 1315/4885PKM 3187/4885CYP3A4 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.